Figure 3: SMC-based combination treatment results in long-term immunological anti-tumour memory. | Nature Communications

Figure 3: SMC-based combination treatment results in long-term immunological anti-tumour memory.

From: Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma

Figure 3

(a) CT-2A cells were treated for 24 h with vehicle or 5 μM LCL161 (SMC) and 0.01% BSA, 1 ng ml−1 TNF-α, 250 U ml−1 IFN-β or 0.1 MOI of VSVΔ51, and viable cells (Zombie Green negative) were analysed by flow cytometry using the indicated antibodies. Representative data from at three independent experiments using biological replicates. (b,c) Naive mice or mice previously cured with SMC-based treatments of mammary fat pad EMT6 (mammary carcinoma, b) or intracranial CT-2A (glioblastoma, c) tumours were reinjected with EMT6 or mammary carcinoma 4T1 cells within the mammary fat pad or with CT-2A cells s.c. or i.c. Cells were implanted at 180 days initial post-implantation. Data represent the Kaplan–Meier curve depicting mouse survival. Log-rank with Holm–Sidak multiple comparison (compared with method of implantation): *P<0.05; **P<0.01; ***P<0.001. Numbers in parentheses represent number of mice per group.

Back to article page